Convergence Insufficiency Treatment Trial (CITT)
Convergence Insufficiency Treatment Trial (CITT)
批准号:
7285587
负责人:
SUSANNA M TAMKINS
金额:
$4.6万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2008-08-31
关键词:
AftercareAgeClinicalClinical TrialsClinical Trials DesignConvergence InsufficiencyDataData CollectionData Coordinating CenterDocumentationEligibility DeterminationEnrollmentEquipmentEyeGoalsGrantHispanicsHome environmentHuman ResourcesInstitutesManualsMasksMeasurementMeasuresMethodsMulti-Institutional Clinical TrialOhioOptometryOrthopticsOutcomeOutcome MeasureParticipantPatientsPennsylvaniaPhasePlacebo ControlPlacebosPopulation StudyProceduresProtocols documentationRandomizedRandomized Clinical TrialsRecruitment ActivityResearchScoreSigns and SymptomsSiteStandards of Weights and MeasuresStrabismusSurveysSymptomsTestingTimeTreatment ProtocolsUniversitiesUpper armVisionVisitWeekbasecollegecompare effectivenessdesignexperiencefollow-upimprovedmedical schoolsmemberprospectivetreatment durationtreatment trial
中文摘要
描述(由申请人提供):本提案旨在将迈阿密大学医学院的巴斯科姆帕尔默眼科研究所作为会聚不足治疗试验(CITT)的临床中心。CITT是一项多中心随机临床试验,旨在比较会聚功能不全(CI)患者的两种积极治疗方法的有效性。 在拟定的随机临床试验中,392例年龄在9 - 30岁之间的患者将被随机分配至:1)基于办公室的视力治疗/矫正,2)基于办公室的安慰剂视力治疗/矫正,3)标准基于家庭的铅笔俯卧撑治疗,和4)基于办公室的铅笔俯卧撑治疗。CI体征和症状的测量将在基线时进行,并在12周治疗期间由设盲的检查者每4周一次进行。治疗12周后成功的患者将接受12个月的随访。主要结果测量是在会聚不足症状调查中的得分。次要结局指标将包括近点会聚和近点正融合聚散度。 我们在巴斯科姆帕尔默眼科研究所的目标是识别、筛选和评估潜在的研究参与者,并招募合格的患者参加会聚不足治疗试验。本申请记录了巴斯科姆帕尔默眼科研究所在24个月招募期内招募至少45例患者,并在治疗完成后保留每例成功治疗的患者一年的能力。还提供了文件,以确认巴斯科姆帕尔默眼科研究所拥有按照CITT程序手册(MOP)开展研究的人员、设备、设施和临床试验经验。CITT原理、设计和方法的完整详细信息包含在MOP中,该MOP与研究主席和数据协调中心申请一起单独提交。除了巴斯科姆帕尔默眼科研究所外,还将有8个其他临床中心,其中包括宾夕法尼亚验光学院的研究主席和俄亥俄州州立大学的数据协调中心。
英文摘要
DESCRIPTION (provided by applicant): This proposal is for the Bascom Palmer Eye Institute of the University of Miami, School of Medicine to serve as a clinical center in the Convergence Insufficiency Treatment Trial (CITT). The CITT is a multi-center randomized clinical trial designed to compare the effectiveness of two active treatment approaches for patients with convergence insufficiency (CI). In the proposed randomized clinical trial 392 patients between the ages of 9 and 30 years will be randomly assigned to: 1) office-based vision therapy/orthoptics, 2) placebo office-based vision therapy/orthoptics, 3) standard home-based pencil push-up therapy, and 4) office-based pencil push-up therapy. Measurements of the signs and symptoms of CI will be made at baseline, and by masked examiners every 4 weeks during the 12-week treatment phase. Patients who are successful after 12 weeks of treatment will be followed for 12 months. The primary outcome measure is the score on the Convergence Insufficiency Symptom Survey. Secondary outcome measures will include the near point of convergence and positive fusional vergence at near. Our objective at the Bascom Palmer Eye Institute is to identify, screen and evaluate potential study participants and to enroll eligible patients in the Convergence Insufficiency Treatment Trial. This application documents the ability of Bascom Palmer Eye Institute to enroll at least 45 patients within the 24 month recruitment period, and to retain each successfully treated patient for one year after completion of treatment. Documentation is also provided to confirm the Bascom Palmer Eye Institute has the personnel, equipment, facilities and clinical trials experience to conduct the study in accordance with the CITT Manual of Procedures (MOP). Complete details of the CITT rationale, design, and methods are contained in the MOP, which is submitted separately with the Study Chair and Data Coordinating Center applications. In addition to the Bascom Palmer Eye Institute, there will be 8 other clinical centers with the Study Chair at the Pennsylvania College of Optometry and the Data Coordinating Center at The Ohio State University.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Convergence Insufficiency Treatment Trial Attention and Reading Trial (CITT-ART)
-
批准号:8609620
-
项目类别:
-
资助金额:$16.36万
-
财政年份:2014
-
负责人:SUSANNA M TAMKINS
-
依托单位:
Convergence Insufficiency Treatment Trial Attention and Reading Trial (CITT-ART)
-
批准号:8842638
-
项目类别:
-
资助金额:$11.84万
-
财政年份:2014
-
负责人:SUSANNA M TAMKINS
-
依托单位:
Convergence Insufficiency Treatment Trial (CITT)
-
批准号:7050269
-
项目类别:
-
资助金额:$3.64万
-
财政年份:2004
-
负责人:SUSANNA M TAMKINS
-
依托单位:
Convergence Insufficiency Treatment Trial (CITT)
-
批准号:6728133
-
项目类别:
-
资助金额:$14.54万
-
财政年份:2004
-
负责人:SUSANNA M TAMKINS
-
依托单位:
Convergence Insufficiency Treatment Trial (CITT)
-
批准号:7117224
-
项目类别:
-
资助金额:$8.18万
-
财政年份:2004
-
负责人:SUSANNA M TAMKINS
-
依托单位:
Convergence Insufficiency Treatment Trial (CITT)
-
批准号:6954636
-
项目类别:
-
资助金额:$19.05万
-
财政年份:2004
-
负责人:SUSANNA M TAMKINS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: